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Abstract
In 1996, federal regulations were put into effect that allowed enrollment of critically ill or injured patients
into Food and Drug Administration (FDA)-regulated clinical trials using an exception from informed
consent (EFIC) under narrowly prescribed research circumstances. Despite the low likelihood that a legally
authorized representative (LAR) would be present within the interventional time frame, the EFIC
regulations require the availability of an informed consent process, to be applied if an LAR is present and
able to provide prospective consent for patient enrollment into the trial. The purpose of this article is to
describe a series of unanticipated consent-related questions arising when a potential surrogate decision-
maker appeared to be available at the time of patient enrollment into a trial proceeding under EFIC.
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I n 1996 federal regulations were put into effect thatallowed enrollment of critically ill or injured patientsinto U.S. Food and Drug Administration (FDA)-reg-
ulated clinical trials using an exception from informed
consent (EFIC).1 These regulations are applicable under
narrow clinical circumstances when the critical condi-
tion of the patient and the rapidity with which the inter-
vention must be initiated make it impracticable to
obtain prospective informed consent from the patient or
his/her legally authorized representative (LAR). Other
criteria, such as lack of adequate alternative therapies,
acceptable risk to beneﬁt proﬁle, and possible direct
beneﬁt to the patient, are also required.
The FDA understood that the EFIC regulations would
be applied infrequently and in trials in which the patient
populations, interventions, and situational constraints
vary. The rules therefore allow substantial latitude for
investigators and institutional research boards (IRBs)
and require considerable interpretation. In 2011, the FDA
released a guidance document on EFIC that incorporated
examples from accumulated experience (which was mini-
mally updated in 2013).2 Challenges remain, however, in
development of optimal approaches to EFIC trials and
application of these regulations. The purpose of this arti-
cle is to describe a series of unanticipated consent related
questions arising when a potential surrogate decision-
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maker appeared to be available at the time of patient
enrollment into a trial proceeding under EFIC.
BACKGROUND
Although the conditions of studies covered under EFIC
generally make prospective informed consent impossible,
investigators are required to develop an informed con-
sent process in the event that prospective informed con-
sent can be obtained in an individual case. Consent in
these severe critical circumstances would likely come
from the subject’s LAR, with the hierarchy of LARs
established by state law. In many EFIC circumstances,
prospective consent is not feasible from the LAR
because the LAR is not present within the intervention’s
time window or the subject (and hence the LAR) is not
identiﬁable. Occasionally, an LAR may be present, but
the investigational agent or other study intervention
must be given before an adequate consent discuss-
ion can be conducted and an informed prospective deci-
sion can be made by the LAR regarding enrollment of
the subject in the trial.
In 2009, the Neurological Emergencies Treatment
Trials (NETT) research network3 began an interven-
tional trial for patients with moderate to severe trau-
matic brain injury (ProTECT-III). The trial involved
treatment with progesterone as a neuroprotective
agent, initiated within 4 hours of injury (and with a
goal of initiation within 2 hours of injury), and contin-
ued as an intravenous infusion for 96 hours. Partici-
pants were followed for 6 months. Patients eligible for
this study were cognitively impaired (Glasgow Coma
Scale 4 to 12) and not capable of providing meaning-
ful prospective informed consent for research partici-
pation for themselves.
The investigators proposed a 1-hour window after
the patient’s ED arrival that would be dedicated to a
good faith effort to locate the LAR so that the patient
might be eligible for enrollment with prospective surro-
gate consent. If the LAR presented within the hour, an
informed consent process took place, during which the
LAR decided whether to enroll the patient in the trial.
The 1-hour window was chosen keeping in mind the
inherent delay inevitable in obtaining test results
required to satisfy the inclusion criteria. Further, the
allotment was felt to be respectful of patient autonomy
and consistent with the spirit of the regulations. If no
LAR was present within 1 hour of patient arrival, an eli-
gible patient could be entered into the study under
EFIC. Consent for continued participation was then
pursued from the subject or from an LAR as soon as
feasible. Previous work by the study investigators indi-
cated that suitable surrogates are often not present and
available to participate in consent processes within the
narrow treatment window for this intervention.4 There-
fore the FDA approved an investigational new drug
application for this trial that allowed subjects to be
enrolled under EFIC. The consenting mechanism of the
trial is shown in Figure 1.
The NETT clinical coordinating center has a dedicated
human subjects coordinator and a human subjects
working group (HSWG) tasked with overseeing human
subjects protection issues related to all NETT trials.5
The case studies presented here are cases reported to
the HSWG for discussion of ethical challenges that
arose during the conduct of the ProTECT-III trial. The
cases present the complexities of consent by an LAR
within the context of an EFIC study. In addition, each
case also describes the challenges that arise when
attempting to determine how the case ﬁts into the
established (and approved) consenting paradigm for the
study itself and how the case, as it was resolved, satis-
ﬁes the regulatory requirements for surrogate consent
when it is possible within an EFIC study.
CASE STUDIES (TABLE 1)
Case 1: “Like a Brother”
A severely injured patient arrived at the emergency
department (ED) after a motorcycle crash. The patient
met inclusion criteria for the ProTECT-III study. Shortly
afterward, within the 1-hour time frame established for
the physical presence of an LAR, a man arrived who
identiﬁed himself as the patient’s brother, and the site
study coordinators considered him to be the patient’s
available LAR. The LAR was informed of the study and
agreed to provide prospective informed consent for the
patient’s enrollment. Several hours later, it was discov-
ered that the consenting individual was not the patient’s
biological sibling, but rather the subject’s “Harley
brother.”
Discussion. In this case, the Harley brother was
thought to have a legally recognized relationship with
the patient that he in fact did not have. When it became
clear that the Harley brother was not the patient’s LAR,
pursuit of a valid consent from a real LAR was sought,
but no LAR was immediately found. The ProTECT-III
hotline was notiﬁed and the HSWG determined that the
enrollment should be considered an EFIC enrollment,
Figure 1. Consenting paradigm for ProTECT-III. LAR = legally authorized representative; EFIC = exception from informed consent.
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since the assumed LAR was not a true LAR. Ultimately,
the subject himself was able to give meaningful consent
for continued participation, 11 days after enrollment.
The EFIC regulations default to EFIC enrollment
whenever there is a question of the presence or identity
of an LAR. In this case, the enrollment was deemed an
EFIC enrollment just as it would have been had the
Harley brother not been present. EFIC studies are
unique in this respect, differing from standard clini-
cal research, because enrollment does not depend on
prospective consent; the default of enrollment is in large
part justiﬁed by the additional protections built into the
EFIC regulations.
Tension related to the EFIC regulations might, how-
ever, have arisen in this case of the “false” surrogate if,
for example, a true LAR or the patient himself disagreed
with the decision made by the false surrogate. For
example, the patient would not have been enrolled into
the study if the Harley brother, assumed to be the true
LAR, had declined enrollment. By the time the discovery
was made that a true LAR was not present, the time
frame for study enrollment had passed.
Most states have statutes that deﬁne the hierarchy of
LARs related to clinical decision-making for incapaci-
tated patients and describe how this should be docu-
mented. States may vary in their interpretation of who
constitutes an appropriate potential decision-maker. In
some, state law provides LAR status to friends or close
friends as the last resort (see for example Georgia state
law O.C.G.A 31-9-26).
Further, even in states where no statute exists, many
hospitals honor a friend’s greater knowledge of the
intent of the patient. However, it is not clear if the same
rules of hierarchy would hold for research study enroll-
ment (rather than clinical care) of an incapacitated
patient. In emergency research situations, where time is
limited, it is important to communicate clearly with the
presumed surrogate what they are claiming and agree-
ing to. When a true LAR is not present within the allot-
ted time frame, the EFIC regulations allow enrollment
of the patient into the trial.
This case thus raises important conceptual questions
about the role of surrogates in EFIC research. If a close
and long-term established relationship exists between
the potential surrogate and the patient, what role
should that person play in enrollment decisions when
the default in EFIC studies is enrollment in the absence
of an LAR? The EFIC regulations state that an LAR can
provide consent for research enrollment for the inca-
pacitated patient and that investigators should offer the
family an opportunity for refusal when appropriate.1
Would nonenrollment based on objection by a non–
Table 1
Summary of Cases and Ethical and Practical Challenges
Case
Barrier to
Effective LAR Core Tension Guiding Principle(s)
Ethical Challenge(s)/
Questions
Harley
brother • Lacks legal status
• Patient’s preferences
unknown
• Ethical vs. legal
surrogacy
• Respect legitimate
refusals
• Ensure surrogate has
appropriate ethical
standing
• No criteria for relying on a
non–legally recognized
surrogate, particularly in
context of “opportunity to
refuse”
Intoxicated
LAR • Intoxication impairs
LAR’s capacity to
serve as a surrogate
• Desire for surrogate
decision-making vs.
desire not to act on
decisions in context
of incapacity
• Recognize patients’
wishes as expressed
by LAR
• LAR must have capacity
to make meaningful
decision
• If an incapacitated potential
LAR wants to refuse
participation, are criteria for
honoring refusal different
than those for providing
consent?
Refusal to
be LAR • LAR is capacitated
but reluctant
• LAR believes the
significant other
should make
decisions.
• Preference for
surrogate decision-
making rather than
EFIC vs. forcing
someone to act in a
capacity in which
they are
uncomfortable
• Do not enroll if consent
is “possible” but not
obtained.
• Avoid incentivizing
“opting out” of decision-
making.
• Cannot force people to act
as a surrogate decision-
maker
• Refusal of an LAR to serve
in that role may reflect
patient’s preferences
regarding research
enrollment
Geographically
distant LAR • LAR is identified
but there is a
communication
barrier based on
geographic
distance
• Desire to act on
individuals’ wishes
(as expressed by
LAR) versus a
suboptimally
informed decision
• Opportunity to object
should be offered unless
communication barrier
prevents adequate
discussion to meet
criteria for acceptable
refusal
• Uncertainty regarding
necessary level of
understanding for refusal to
be ethically valid
• Uncertain/unknown
whether stress imposed by
discussion over the phone
or involvement in decisions
is preferred by patients/
surrogates
LAR = legally authorized representative.
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family member such as the Harley brother be consid-
ered appropriate if it was deemed that the non–family
member was legitimately aware of patient preferences?
If so, how would this knowledge be veriﬁed and what
would be the consequences? What if the extent of the
connection was unclear? Tensions between legal and
ethical authorization as a surrogate are well known, but
their speciﬁc implications in the context of EFIC
research have not been fully addressed.
Case 2: “Too Drunk to Say”
A patient was transported to the ED shortly after sus-
taining a severe TBI. The study team had been notiﬁed
prior to his arrival, so the team was able to immediately
screen him for study eligibility. It was determined that
the patient was eligible, pending the conﬁdential serum
alcohol level results. During the preliminary screening
process, the on-duty ED social worker was asked to
help contact family and the LAR. The social worker
notiﬁed the study coordinators that the patient’s mother
and girlfriend were at the bar with the patient at the
time of the incident and were on their way to the hospi-
tal. Since the family’s arrival was anticipated to be
within 1 hour of patient arrival, the study team pro-
ceeded under the protocol with the intent to seek pro-
spective consent upon LAR arrival.
When the family arrived, the charge nurse informed
the study team that the LAR appeared to be intoxicated.
The social worker, who also interacted with the family,
concurred that the family members, including the LAR,
were all intoxicated and, further, that they were too
inebriated to participate in any meaningful decision-
making or consent process. Based on this information,
the family was not approached by the study team. The
ProTECT-III hotline was contacted for guidance and a
decision was made to enroll the patient under EFIC.
The team therefore enrolled the patient with EFIC
despite the presence of an LAR within the study’s
1-hour time frame for LAR consent.
Discussion. In subsequent discussions, the HSWG
agreed with the study team that an LAR who is
impaired from intoxication obviously cannot engage in
a meaningful conversation and participate in an
informed consent process. This case raises the issue of
capacity assessment of LARs and how this may result in
tension within the context of an EFIC study. What
should be done if an LAR is present but is deemed inca-
pable of making an informed decision to accept or
decline study enrollment? How can it be determined
that EFIC is the correct default in this circumstance?
It must be acknowledged that there are many circum-
stances when family members and LARs lack capacity
to provide informed decisions. Examples of this include
when the family members are also critically injured in
the same accident, when they are minors, when they
are demented or developmentally delayed, or when they
are very intoxicated. Allowing EFIC enrollments when
family members and LARs lack capacity avoids exclu-
sion of eligible subjects from enrollment. At the same
time, the temptation to enroll patients can lead to a
thoughtless and rapid determination of incapacity
when, in fact, more careful scrutiny and effort may
resolve the question of the capacity of the LAR. Tension
exists for the investigator, who obviously wants to
enroll the patient and whose research intervention is
very time-sensitive, but who also is required and
expected to follow ethical procedures, to adhere to the
regulations that govern ethical research, to apply the
patient safeguards inherent in the EFIC regulations, and
to act in a manner that respects and protects the inca-
pacitated patient’s rights. Indeed, this tension may be
perceived as a conﬂict of interest for the investigators,
but it is not. Because EFIC enrollments are followed as
soon as possible by notiﬁcation and consent to con-
tinue, there is no advantage to the investigator to enroll
under EFIC someone who will withdraw immediately
thereafter. While the tension is largely mitigated by this
requirement, determination of LAR capacity in emer-
gency research circumstances remains an uncertain and
unstudied challenge.
Determination of incapacity or competence is rarely
straightforward, even in the best of situations. These
decisions are often subjective and can place the
research team in a difﬁcult situation. Ideally, other non-
study personnel should determine the capacity of the
LAR to give prospective consent. In the acute care set-
ting, this may not be possible. If the study team begins
the discussion of the study with the LAR who is then
determined to be incapacitated, what should be done if
that person declines the study? Is this refusal truly
informed? How informed does informed refusal need
to be? What constitutes an adequate assessment of
capacity?
The HSWG recommended that the study team itself
be responsible for ensuring careful capacity assess-
ment before determining that someone is not capable
of being an LAR. Such a determination should be
based on reliable historical or clinical information.
Taking the word of another without the research
team’s own assessment may raise questions about the
team and overeagerness to enroll the patient without
attending to the capacity assessment of the LAR. In
addition, to avoid the perception that study teams
determine incapacity in order to enroll patients, we
suggest that the threshold be high for determining
incapacity, but low for honoring refusals. As a further
protection against perceived conﬂict of interest, and to
be sure these decisions are highly transparent and can
be tracked, the study team should notify the on-call
principal investigator prior to enrolling using EFIC.
The HSWG also recommended that, because it is ubiq-
uitous, emotional impairment alone not be considered
as a basis for incapacity (although this will be dis-
cussed below). In addition, whenever a study team
enrolls under EFIC in situations where the LAR was
present but is felt to lack capacity, the case should be
reviewed in detail by committees such as the NETT
HSWG to track such enrollments and recommend
improvements to this interpretation or implementation
as needed.
Case 3: “Able and Authorized”
A man with a severe TBI was transported to the ED
after a serious motor vehicle collision. His mother was
present almost immediately (within the 1-hour time
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frame for ProTECT-III LAR enrollment). She was
approached to provide prospective consent for study
enrollment. She had no objection to the patient being
enrolled into the study, but felt that the patient’s signiﬁ-
cant other, who was on the way to the hospital, should
be the one to provide prospective surrogate informed
consent.
Discussion. This case raises several important issues
related to surrogate consent. What is the alternative if
an LAR is reluctant to act in that capacity? How can
capacity of an LAR be assessed in the short time frame
of an EFIC study? Should surrogate decision-making
only be done by an LAR? Can investigators determine if
an LAR’s indecisiveness is due to situational incapacity,
reluctance to take responsibility, or uncertainty regard-
ing what the patient may want? Should an LAR’s emo-
tional distress be interpreted as making LAR-provided
consent infeasible?
According to the EFIC regulations and the study pro-
tocol, if present within the established time frame, an
LAR is expected to take responsibility for providing
prospective consent for patient enrollment. The consent-
ing LAR does not necessarily have to be the highest-
ranked LAR in the state-deﬁned hierarchy; however, if
there is conﬂict among multiple LARs who may be pres-
ent, the person highest in the state’s hierarchy should
be approached for decision-making.1 The LAR can seek
input from a signiﬁcant other without LAR standing,
but it is not clear if an LAR can abdicate or reassign the
legal authority and responsibility of being the LAR.
By the protocol of the study, the patient could not be
enrolled under EFIC because an LAR was present
within the 1-hour window, even though she was unwill-
ing to act in that capacity. At ﬁrst glance, it would seem
that an LAR who refuses to act in that capacity is equiv-
alent to no LAR at all, and that in both cases, the default
should be to EFIC enrollment. However, the study pro-
tocol was explicitly written to remove any incentive on
the part of the study team to consider an LAR inappro-
priate to enroll the subject under EFIC. Therefore, this
patient was not enrolled in ProTECT-III.
The FDA’s guidance on EFIC does not address the
issue of the present but reluctant LAR. Consultation
with the hospital or IRB attorney may provide guidance,
if practicable in a timely fashion. A more feasible
approach may involve having a very short, focused con-
versation with the LAR (in this case the mother),
designed to identify whether the subject is someone
who would generally not want to be included in this or
any research study. Such a process of “informed refu-
sal” has been suggested as a possible approach to con-
sent challenges in other kinds of acute care research7
and may provide a balance between respecting the sub-
ject’s autonomy and the mother’s desire not to serve as
an LAR. This process may be appropriate if there is real
reason to believe that the mother is simply not in a posi-
tion to comprehend the necessary information and
make a fully informed decision at that moment, but may
be willing to make an informed refusal that enrollment
would be against the son’s wishes.
Informed refusal or some lower level of involvement
in the enrollment decision is consistent with the EFIC
regulatory provisions. EFIC regulations have estab-
lished a lower threshold of legitimacy for objections to
enrollment than is accepted for consenting to enroll-
ment. Family members, regardless of position on the
state hierarchy of LARs, are required to have the
opportunity to object to study enrollment for their fam-
ily member (if feasible), but non-LAR family members
cannot consent to enrollment.2 A case such as this one,
with an LAR who does not appear to object to enroll-
ment, but does not want to act as an ofﬁcial surrogate,
is not explicitly covered in the regulations.
Of course, the LAR could refuse to engage in an
informed refusal discussion as well, forcing the team to
decide whether to exclude the patient from the study or
to enroll under EFIC. Because the clinical conditions
that qualify for EFIC research are exceedingly stressful
on families, and research decisions often are foreign,
circumstances in which potential LARs do not feel they
can act as a surrogate (due to emotional stress or other-
wise) warrant careful consideration. Is this mother
refusing to act as an LAR because she does not feel
knowledgeable enough to speak on behalf of the
patient? Although challenging for investigators, this in
and of itself is not enough to preclude an informed con-
sent discussion, and it is important to discuss the role of
the LAR and what she needs to know or understand to
function as an LAR. Is she unable or reluctant to focus
on the research issues because she is distraught over
the severe life-threatening circumstances her adult child
is in? How can study teams separate situational impair-
ment from other causes of incapacity?
Most family members are expected to have some situ-
ational impairment related to the rapid pace and strong
emotional content of communication and decision-mak-
ing in the emergency setting, just after being notiﬁed of
a loved one’s life-threatening condition. However, situa-
tional impairment itself should not be the sole determi-
nant of defaulting to EFIC enrollment rather than
obtaining LAR prospective consent. In some circum-
stances, situational impairment may likely interfere with
the ability to have a meaningful informed consent dis-
cussion, but the HSWG felt that EFIC should not be
used as a default in the setting of purely “emotional
impairment,” even if the emotional state of the LAR
delays the informed consent discussion.
Like the ﬁrst case, this case also illustrates the ques-
tion of who is the best surrogate decision-maker. In this
case, the signiﬁcant other may have had greater knowl-
edge of the patient’s wishes, but since the signiﬁcant
other was not a family member or LAR, the signiﬁcant
other could neither consent nor decline enrollment. Is
there any justiﬁcation for handling surrogate decision-
making in such situations differently in the context of
an EFIC study? If so, who would determine this? The
conﬂict between the legal and ethical representative cre-
ates a difﬁcult conﬂict between respect for autonomy
within the framework of the study, included to address
the spirit of the regulations, and the need to follow the
letter of the law.
Case 4: “Remote and Minimally Informed”
The patient was on a motorcycle trip with a friend when
he sustained a TBI. He was from another state, but was
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brought to the local ED where he was treated and found
to be eligible for inclusion in ProTECT-III. The subject’s
friend was not his LAR and therefore was not asked for
consent for or given the opportunity to object to the
study enrollment. Because no LAR was immediately
available, as the friend was not a relative and the patient’s
wife was out of state, the patient was enrolled under
EFIC.
Most hospitals restrict the information provided to
family members by telephone about acutely critically ill
or injured patients, so that such information can be
communicated in the hospital in a more controlled and
supportive environment. However, most institutions
allow some clinical information to be communicated by
telephone when relatives are remote and unlikely to be
able to arrive immediately. However, in this case, the
hospital policy was to provide minimal clinical informa-
tion over the phone, so the friend (and not a clinician)
relayed the patient’s clinical information to the patient’s
wife. Since the wife had not been provided any clinical
information from the treating team, the investigators
felt that it was inappropriate to describe the study and
her husband’s eligibility for enrollment until her antici-
pated arrival the next day. In fact, the study protocol
explicitly excluded a phone discussion prior to clinical
notiﬁcation by the treating team. She was therefore also
not provided the opportunity to object prior to the
enrollment. Consent was eventually obtained for contin-
ued ProTECT-III participation from the wife, after she
was able to travel by airplane to the treating hospital.
Although she had no concerns about the patient’s treat-
ment or enrollment, she expressed some resentment
about the lack of clinical information she received and
not being informed of the research study over the
phone in advance of enrollment.
Discussion. In most clinical trials, in-person consent
for enrollment is required because of ethical concerns
about the quality of consent conversations that may take
place over the telephone and legal concerns about the
ability to document the appropriateness of the surro-
gate when that person is not present.8 In these situa-
tions, if signed consent documenting the informed
consent process cannot be obtained in person from the
patient or a suitable surrogate decision-maker, an indi-
vidual is simply not enrolled in the trial. When a trial is
approved for EFIC, however, a unique situation arises.
The default position is to enroll the patient rather than
not to enroll the patient.
Consistent with these general regulatory require-
ments regarding signed consent to document the
informed consent process, the EFIC regulations do not
contain any provisions that allow for consent discus-
sions to occur with an LAR over the telephone.1,2 How-
ever, the EFIC regulations do clearly state that where
possible a family member should be given the opportu-
nity to object prior to study enrollment and that such an
objection does not have to be in writing.2 Speciﬁc
allowable communication modalities by which this con-
versation can occur are not speciﬁed. In the case pre-
sented here, the investigators felt that the severe clinical
condition of the patient and the LAR’s lack of direct
communication with the treating team created an
uncomfortable situation that precluded a meaningful
discussion of research options.
In the context of the EFIC regulations, and subse-
quently knowing that the wife was upset about not being
informed, the role of a potential telephone conversation
with the patient’s wife warrants reexamination. There
are, in fact, two ways to view this conversation: 1) as a
true informed consent discussion or 2) as an opportunity
for refusal of enrollment. This distinction is important,
because the standards for refusal are generally accepted
to be lower than the standards for consent.7,9 While
there are reasons to question whether a consent conver-
sation conducted over the phone is sufﬁciently informed
and ethically valid, there are some reasons to believe that
a refusal in this context may be. If, for example, the
patient’s wife had told investigators that her husband
would not want to be included in any research protocols
in the context of acute TBI and there was no reason to
question the legitimacy of this preference, the patient
should probably not be enrolled. In contrast, if the
patient’s wife did not voice objections to enrollment after
an appropriate telephone explanation of the patient’s
status and a very brief summary of the ProTECT-III trial,
enrollment under EFIC seems justiﬁable.
This case was complicated by the hospital’s policy not
to release clinical information over the phone, but this
is an extreme interpretation of a common hospital prac-
tice. This policy created ethical tension for the investiga-
tors. The HSWG suggests that when important
research-related discussions need to occur and the
default in the absence of an LAR is enrollment using
EFIC, disclosure should probably take place to allow the
opportunity to object to enrollment, as is consistent
with the EFIC regulations. Ideally, depending on the
expected delay until the LAR’s arrival, the patient’s clini-
cal status would have been provided by the treating
team to the wife over the phone. This would have been
followed by a very brief description of the ProTECT-III
study and an opportunity for her to ask questions and
decline participation if that is what she wanted to do. If
she did not object, the patient would be enrolled with
EFIC, based on absence of true consent (but no objec-
tion). The wife would then go through a formal, in-per-
son consent process for continued study participation
upon arrival at the site. This practice allows for maximal
respect for the patient’s wishes but recognizes the limi-
tations of telephone conversations.
It could, however, also be argued that the need to
allow opportunity for objection to an EFIC enrollment
should be dependent on the nature of the study itself.
For example, some experimental interventions are
known to present little additional medical risk at the
time of intervention and have no known dangerous
complications. In these circumstances, a telephone com-
munication simply to provide an opportunity to object
may be less important than when a study intervention
carries a greater risk.
From a practical standpoint, however, any conversa-
tion about research enrollment is difﬁcult if the patient’s
clinical status has not yet been described by the treating
team and the investigator cannot directly assess the
capacity of the LAR to understand the research discus-
sion in the face of serious and stress-producing circum-
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stances. Clinical policy and research policy need to be
harmonized. In this cases, the clinical policy of not dis-
closing information resulted in a suboptimal approach
to EFIC research enrollment. Research enrollment in
an EFIC study should be considered an extenuating
circumstance if a hospital does not have a policy to
allow disclosure of clinical information over the phone
when the LAR is coming from a long distance.
Another related ethical challenge raised by this case
relates to the proper role of the patient’s friend. Can the
friend serve as a “suboptimal” but available LAR? Can
the wife authorize the friend to give consent on her
behalf? Can the friend refuse enrollment? Although
common sense and ethical theory may permit a good
faith answer, the legal requirements do not address
these unusual circumstances. There may be relevant
state laws, and legal consul may help ascertain how
they apply in similar circumstances.
CONCLUSIONS
These cases describe challenges arising when prospec-
tive informed consent appeared to be possible in the
context of an exception from informed consent study.
Each case created an unanticipated ethical tension
related to the legally authorized representative. The ten-
sion typically involved some form of trade-off between
less informed, lower-quality consent decisions at the
present time and more informed, higher-quality deci-
sions later. Although these cases are related to a single
research protocol and arose because of the trial-speciﬁc
consent paradigm of ProTECT-III, the ethical issues and
tensions that are described are mostly generalizable to
other exception from informed consent studies.
When the regulations and their guidance were writ-
ten, the nuances described above could not have been
anticipated. It is likely that many other such cases have
occurred in other studies, but there has been little
reporting of such issues. Best practices for exception
from informed consent studies have not been estab-
lished, but the development of a human subjects working
group allowed thoughtful discussion and deliberation
of cases to inform a consistent subsequent practice.
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